Novo Nordisk has taken another step towards expanding beyond its heartlands of diabetes and obesity with a deal to buy US biotech Corvidia Therapeutics and its lead drug for chronic kidney disease ...

Currently, in Phase III trials for patients with chronic kidney disease, Ziltivekimab became part of Novo Nordisk's portfolio after the company acquired Corvidia Therapeutics in June 2020 for USD ...

Results suggest Novo Nordisk was on the right track with its $2.1 billion acquisition of Corvidia Therapeutics in June last year, The deal saw the firm begin to explore new markets after making ...

Novo Nordisk A/S's CagriSema faces challenges, yet new trials aim to enhance efficacy, rival Eli Lilly in obesity treatments, ...

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.

Novo Nordisk A/S (NYSE: NVO) has declared that its GLP-1 drugs for chronic obesity, under the brands Ozempic and Wegovy, are ...

Novo Nordisk's U.S.-listed shares fell Monday morning following the release of data for a new phase 3 clinical trial of its in-development weight loss drug CagriSema.

Novo Nordisk reported results on its next-generation obesity drug in diabetes patients, including data on weight loss that ...

Novo Nordisk (NVO) released clinical trial results for its potential Ozempic successor on Monday, disappointing Wall Street ...

Novo Nordisk stock has fallen roughly 40% from a peak it reached last June. The U.S. Food and Drug Administration recently confirmed Novo Nordisk is producing enough Ozempic and Wegovy to meet demand.